Fundraising Fox
Evox Therapeutics
Founded 2016 · 36 employees on LinkedIn · 11 known investors
Find your way into Evox Therapeutics
Sign up to see every warm intro you have to Evox Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Evox Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases. The therapies target the central nervous system to address the root cause of neurodegeneration.
Investors · 11
How we know: GV (Google Ventures)'s portfolio page · funding news · pharmaceutical-technology.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Oxford Science Enterprises's portfolio page · Not right? Tell us
How we know: funding news · pharmaceutical-technology.com · Not right? Tell us
How we know: funding news · Not right? Tell us
Also in the syndicate · 5
Funding
SEC filings, press & company announcements$45.4M disclosed across 1 of 2 rounds · 2018–2021
- Undisclosed amountSeries CFeb 2021Source ↗
- $45.4MSeries BSep 2018 · 3 sources
Redmill Group (lead), Borealis Ventures, Cowen Healthcare Investments, GV (formerly Google Ventures), Oxford Sciences Innovation, Oxford University, Panacea Healthcare Venture
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does Evox Therapeutics do?
- Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases. The therapies target the central nervous system to address the root cause of neurodegeneration.
- Who are Evox Therapeutics's investors?
- Evox Therapeutics's investors include GV (Google Ventures), OrbiMed, Oxford Science Enterprises, Panacea Venture, Cowen Healthcare Investments, REDMILE.
- How much funding has Evox Therapeutics raised?
- Evox Therapeutics has disclosed $45.4M raised across 1 of its 2 known rounds.